Table 1. Demographic and Treatment Characteristics of Survivors Exposed to CNS-Directed Therapy (N= 1304).
Mean | SD | |
---|---|---|
Age at Evaluation (years) | 31.6 | 7.9 |
Age at Diagnosis (years) | 7.5 | 5.0 |
|
||
N | %* | |
|
||
Age at Evaluation (years) | ||
18-30 | 637 | 48.8 |
31-40 | 472 | 36.2 |
>40 | 195 | 15.0 |
Age at Diagnosis (years) | ||
0-4 | 486 | 37.3 |
5-9 | 368 | 28.2 |
10-14 | 306 | 23.5 |
≥15 | 144 | 11.0 |
Time since Diagnosis (years) | ||
10-19 | 439 | 33.7 |
≥20 | 865 | 66.3 |
Gender | ||
Male | 654 | 50.2 |
Female | 650 | 49.8 |
Ethnicity | ||
Caucasian | 1145 | 87.8 |
Other | 159 | 12.2 |
Education | ||
≤Some college | 790 | 62.5 |
≥College | 474 | 37.5 |
Marital Status | ||
Single, never married | 488 | 38.6 |
Married, living as married | 601 | 47.6 |
Divorced, no longer living as married | 175 | 13.8 |
Living Arrangement** | ||
Dependent | 390 | 29.9 |
Independent | 914 | 70.1 |
Household Income | ||
<$40,000 | 520 | 47.2 |
≥$40,000 | 582 | 52.8 |
Health Insurance | ||
Yes | 996 | 76.7 |
No | 302 | 23.3 |
Dental Insurance | ||
Yes | 696 | 55.8 |
No | 552 | 44.2 |
Diagnosis+ | ||
Leukemia | 872 | 66.9 |
Lymphoma | 129 | 9.9 |
CNS Tumor | 142 | 10.9 |
Embryonal | 26 | 2.0 |
Bone and Soft Tissue Sarcoma | 111 | 8.5 |
Other | 24 | 1.8 |
Radiation+ | ||
Chest | 212 | 16.3 |
Cranial (CRT) | 674 | 51.7 |
Chemotherapy+ | ||
Anthracyclines | 825 | 63.3 |
Alkylating Agents | 860 | 66.0 |
Antimetabolites | 990 | 75.9 |
Anti-Tumor Agents | 67 | 5.1 |
Corticosteriods | 952 | 73.0 |
Platinum | 122 | 9.4 |
CNS Directed Therapy+ | ||
HD/IV/IT/IO MTX‡ | 1036 | 79.5 |
HD Ara-C‡‡ | 105 | 8.1 |
HD/IV/IT/IO MTX and HD Cytarabine | 1057 | 81.1 |
HD/IV/IT/IO MTX and CRT | 1196 | 91.2 |
HD Ara-C and CRT | 725 | 55.6 |
HD/IV/IT/IO MTX, HD Ara-C and CRT | 1199 | 92.0 |
Percentages based on participants with available data
independent living (living alone, with a spouse/roommate or as a caretaker); dependent living (living with parents/family)
variable not included in multivariable models
high dose/intravenous/intrathecal/intra-ommaya methotrexate
high dose cytarabine